Our specific interest pertained to the small molecule inhibitors of the Bcr–Abl kinase such as nilotinib (1) and ponatinib (2) (Fig. 2), which are used in the clinic for treatment of chronic myeloid leukemia (CML).41 We show that the formed benzanilide and unexpectedly obtained benzothiazole structures both bind the Abl1 tyrosine kinase with nanomolar activity. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.